Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kura Oncology (KURA) FCF Margin (2023 - 2025)

Kura Oncology (KURA) has disclosed FCF Margin for 3 consecutive years, with 649.87% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin rose 6733945.0% to 649.87% in Q4 2025 year-over-year; TTM through Dec 2025 was 187.5%, a 807964.0% increase, with the full-year FY2025 number at 104.76%, down 35316.0% from a year prior.
  • FCF Margin was 649.87% for Q4 2025 at Kura Oncology, up from 389.9% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 18905.5% in Q1 2025 to a low of 66689.58% in Q4 2024.
  • A 3-year average of 1654.81% and a median of 8711.68% in 2023 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: crashed -7540125bps in 2024, then surged 6733945bps in 2025.
  • Kura Oncology's FCF Margin stood at 8711.68% in 2023, then crashed by -866bps to 66689.58% in 2024, then surged by 101bps to 649.87% in 2025.
  • Per Business Quant, the three most recent readings for KURA's FCF Margin are 649.87% (Q4 2025), 389.9% (Q3 2025), and 18905.5% (Q1 2025).